Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
Jan 03, 2012 Nature speaks with Keim about H5N1 studies -
-
-
Jun 20, 2011 Promising skin-cancer drug nears approval
Share on Twitter
Share on Facebook
Email to a friend
Print Article
Sanuwave adds Southern AZ VA Med Center to diabetes trial
[Source: Business Wire/Biospace.com] - SANUWAVE, Inc., an emerging leader in the development and commercialization of noninvasive, biologic response activating devices in the regenerative medicine segment, has added Southern Arizona VA in Tucson, Arizona as the newest clinical trial site for its Investigational Device Exemption (IDE) clinical trial evaluating Pulsed Acoustic Cellular Expression (“PACE™”) technology and the safety and efficacy of dermaPACE™ in healing diabetic foot ulcers. Dr. Katherine Neiderer will be the Principal Investigator for the site.
For more information: SANUWAVE, Inc. Adds Southern Arizona VA Medical Center to its dermaPACE™ Investigational Device Exemption Clinical Trial for Diabetic Foot Ulcers
Quick Links
- NEW: About the Arizona Center for Civic Leadership
- Arizona Biosciences News
- Arizona BioMap
- Roadmap Progress Updates
- Reports & Multimedia
- Timeline: Arizona's Bio Growth
- Arizona Bio Orgs on Twitter
- Arizona BioBasics
- The Biozona Brand
- Newsletter Signup
Download a new brochure from the Flinn Foundation outlining the 2011 progress on Arizona's Bioscienced Roadmap: a record high in bioscience jobs, plus gains in firms and venture-capital funding. Numerous achievements during the year advanced the core strategies of the Roadmap.
Also, read the full Performance Assessment describing in detail Arizona's 2011 progress on key Roadmap metrics.
